GOT2

Across TCGA pan-cancer cohorts, GOT2 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of GOT2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where GOT2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types GOT2 is over-expressed in tumor, although a few such as CCRCC and HNSC show the opposite, repressed pattern.

CCRCC, HNSC, and LSCC are the cancer types where GOT2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GOT2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	II,III,IV	−0.981	<.001	12	view →
HNSC	All	II,III,IV	−0.556	<.001	11	view →
LSCC	Female	All	+0.743	<.001	8	view →
COAD	All	All	+0.149	.001	6	view →
LUAD	Female	All	+0.338	<.001	5	view →
OV	All	All	+0.452	.049	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

GOT2–CCRCC

Open the CCRCC breakdown →